✦ LIBER ✦

P1-397 Pioglitazone in Alzheimer's disease: rationale and clinical trial design

✍ Scribed by David S. Geldmacher; Gary E. Landreth

Book ID: 117413270
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 320 KB
Volume: 25
Category: Article
ISSN: 0197-4580
DOI: 10.1016/s0197-4580(04)80709-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Antipsychotic Discontinuation in Alz

The Antipsychotic Discontinuation in Alzheimer Disease Trial: Clinical Rationale and Study Design

✍ Devanand, D.P.; Mintzer, Jacobo; Schultz, Susan; Sultzer, David; de la Pena, Dan 📂 Article 📅 2012 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 214 KB

P1-397: The Jerky protein in Alzheimer’s

P1-397: The Jerky protein in Alzheimer’s disease

✍ Evelyn Matthews; Andrew Lindsay; John Stockley; Rivka Ravid; Mary McCaffrey; Cor 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Study design considerations: Conducting

Study design considerations: Conducting global clinical trials in early Alzheimer’s disease

✍ R. J. Schindler 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 58 KB

Study design considerations: Conducting

Study design considerations: Conducting global clinical trials in early Alzheimer’s disease

✍ Schindler, R. J. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 143 KB

P4-343: Omega 3 fatty acids and Alzheime

P4-343: Omega 3 fatty acids and Alzheimer's disease: Trial design and baseline study population characteristics in a clinical trial of docosahexanoic acid for Alzheimer's disease

✍ Quinn, Joseph F.; Raman, Rema; Thomas, Ronald; Ernstrom, Karin; Yurko-Mauro, Kar 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Using modern psychometric methods to imp

Using modern psychometric methods to improve measurement of cognition in Alzheimer’s disease clinical trials: Rationale and approach

✍ Mungas, Dan 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB